fashion -WSS

fashion

author：leisure time 2025-10-01 02:12:28 - browse：538

Neurocrine Biosciences decided to join PhRMA. Adobe

WASHINGTON — Neurocrine Biosciences, a biotech company based in California, has joined the drug lobbying organization PhRMA, the group announced on Thursday.

The addition is a step toward rebuilding PhRMA’s ranks after high-profile departures that followed the passage of Democrats’ drug pricing law, though both Neurocrine and the other company that joined since are smaller than those that exited.

The company is a relatively big spender on lobbying, especially for its size. Neurocrine spent $3.1 million on its federal advocacy efforts last year alone. Compare that with Vertex Pharmaceuticals, which spent virtually the same amount on lobbying, even as it brought in nearly quadruple the net income that Neurocrine Biosciences did last year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Will generative AI in health care meet the fate of IBM's Dr. Watson?

WSS

Readout LOUD podcast: mifepristone case, GLP

Study says nonprofit hospitals fall short in charity care spending

A new approach to psychiatric drug development

For AI in health care standards, federal regulators join with industry group

Washington mulls new rules to avert another Change Healthcare

Readout Newsletter: BridgeBio, Akero, and human embryo models

entertainment

fashion

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Harvard's David Sinclair gets blowback over aging

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

$1 billion proposal to grow Boston, Massachusetts biotech

Peter Hotez and the public health issue of online harassment

He's 19 months old and has one of the world’s rarest diseases

Medicare details structure of new drug price negotiation program

Study says nonprofit hospitals fall short in charity care spending

In age of alternative facts, a scholarly course on calling out crap

Patient advocates debate FDA's accelerated approval process

leisure time

The Readout: Lenmeldy, GLP

Ancient Greek ideas underpin modern concepts of pregnancy

Abortion pill Supreme Court ruling could impact entire drug industry

Medicare drug price negotiation hearing pits pharma v Biden admin

The Readout: Lenmeldy, GLP

Change Healthcare: What is it, why does its cyberattack matter?

leisure time

focus

knowledge

hotspot